Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Regardless of which you choose, Pfizer's (NYSE: PFE) share price has declined during the period. Pfizer's dismal stock ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.

Last year was a strong year in terms of performance and execution by Pfizer, even though its stock took a hit in 2023 due to the decline in revenues and profits. It saw improved performance of its ...

The company's financial performance is recovering faster ... initiatives could serve as a positive catalyst for the stock. Additionally, Pfizer might exceed its announced $4 billion savings ...

The recent formation of the FIBRE Consortium, a collaboration involving Pfizer (NYSE:PFE) and other pharmaceutical partners, ...

It compares these trends to the stock’s performance during the 2008 recession. In contrast, here’s how PFE stock and the broader market performed during the 2007/2008 crisis. PFE stock ...

So while bulls might be disappointed with its stock price performance, it's still feasible to build up a decent passive income stream at a bargain by buying shares of Pfizer and holding them over ...

Let’s understand the company’s strengths and weaknesses to better analyze how to play PFE’s stock in the post-earnings scenario. Sales of PFE’s COVID Products Decline With the end of the ...